A site where you can find recommended contractors for non-clinical testing｜effical " Non-Clinical CROs and Agencies " Experimentica Ltd

Experimentica Ltd

Experimentica Ltd is a nonclinical contract research organization (CRO) specializing in ophthalmology. The company conducts in-house pharmacology and pharmacokinetic studies and operates under GLP-compliant systems to generate data that meet international regulatory standards.
This page provides an overview of Experimentica Ltd’s nonclinical research capabilities and representative ophthalmic disease models.

Features of Experimentica Ltd’s Contract Services for Non-Clinical Studies

Pharmacokinetic profiling to support optimized dosing strategies

Experimentica Ltd conducts preclinical pharmacokinetic (PK) studies to quantitatively assess the absorption, distribution, metabolism, and excretion of candidate compounds.
Multiple routes of administration—including oral, intravenous, and intraocular—are supported. High-sensitivity analyses are performed on plasma, ocular tissues, and aqueous humor using analytical platforms such as LC–MS/MS to characterize systemic and ocular exposure.
These data are used to inform the design of efficacy and safety studies. All studies are conducted under GLP-compliant conditions, ensuring data quality aligned with international standards.

Quantitative evaluation of efficacy and mechanism of action using ophthalmic disease models

Experimentica Ltd’s pharmacology studies leverage a wide range of ophthalmic disease models, including diabetic retinopathy, glaucoma, and dry eye disease, to evaluate the efficacy and mechanism of action of novel drug candidates.
Both in vivo and in vitro studies are supported, with quantitative endpoints derived from AI-based image analysis and biomarker measurements.
Study design, dosing regimens, and evaluation parameters can be flexibly customized according to research objectives, enabling robust assessment of drug efficacy and mechanistic validation.

3 Specialized Pre-clinical CROs for Advanced Drug Discovery

Examples of Disease Models Available at Experimentica Ltd

Oxygen-induced retinopathy (OIR) model

This model induces retinal vessel occlusion and reperfusion through controlled oxygen exposure, reproducing pathological neovascularization. It is widely used for evaluating anti-angiogenic agents such as anti-VEGF therapies.
Retinal vascular architecture can be quantitatively assessed using image-based analysis.

Dry stress and scopolamine-induced dry eye model

By combining scopolamine administration with a low-humidity environment, this model induces reduced tear secretion and corneal epithelial damage.
Therapeutic effects of moisturizing and anti-inflammatory agents can be evaluated using endpoints such as tear volume and corneal damage scores.

Microbead-induced ocular hypertension model

In this glaucoma model, microbeads are injected into the anterior chamber to inhibit aqueous humor outflow and elevate intraocular pressure.
Changes in retinal nerve fiber layer thickness and retinal ganglion cell loss are quantitatively assessed, supporting evaluation of IOP-lowering and neuroprotective therapies.

Experimentica Ltd Non-Clinical Case Study

A preclinical study was conducted to evaluate the efficacy of the anti-VEGF agent aflibercept using an oxygen-induced retinopathy (OIR) model.
By alternately exposing animals to hyperoxic and normoxic conditions, the model successfully reproduced pathological neovascularization driven by vascular occlusion and subsequent reperfusion.
In the treatment group, a marked reduction in neovascular area was observed, along with normalization of vascular architecture.
These results were presented at EVER 2018, demonstrating that the company’s image analysis capabilities and quantitative vascular assessment methods are valuable for supporting the development of anti-angiogenic therapies.

Reference: Experimentica Ltd's official website (https://experimentica.com/solutions/oxygen-induced-retinopathy/)

Experimentica Ltd Company Information

Address	Microkatu 1, P.O. Box 1199, 70211 Kuopio, Finland
Tel	+1 844 393 4393
Website	https://experimentica.com/

3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation

SMC Laboratories, Inc.

Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)

SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.

Consult study design and disease model development
with SMC Laboratories, Inc.

Consult SMC Laboratories
Call us

Safety Studies
Comprehensive Safety Evaluation for FIH Applications

Labcorp Holdings Inc.
(Labcorp Drug Development)

Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)

Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.

Consult Labcorp Holdings Inc.
Discuss GLP/ICH-compliant study design for your FIH submission.

To labcorp.
Call us

Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation

PhoenixBio Co., Ltd.

Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)

PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

Consult Phoenix Bio for PK/PD analysis with a clinical focus

Phoenix Bio.
Call us